BRIEF published on 10/30/2026 at 06:35, 1 day 15 hours ago Nicox: Financial report for the first half of 2026 Financial Results Treasury Ophthalmology NCX 470 Future Strategy
BRIEF published on 09/16/2026 at 07:35, 1 month 15 days ago Nicox: NCX 470 data presentation at the 2026 AAOpt Congress Phase 3 Ophthalmology Nicox NCX 470 AAOpt Congress
PRESS RELEASE published on 09/16/2026 at 07:30, 1 month 15 days ago Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026 Nicox presents key data on NCX 470 at AAOpt Annual Meeting 2026, focusing on glaucoma management. Details on clinical trials and future conference participation Clinical Trials Ophthalmology Nicox NCX 470 AAOpt
BRIEF published on 09/11/2026 at 07:35, 1 month 20 days ago Nicox's NCX 470 NDA Accepted for Review in China Ophthalmology NCX 470 Ocumension Therapeutics China Market NDA Review
PRESS RELEASE published on 09/11/2026 at 07:30, 1 month 20 days ago Nicox Announces NCX 470 NDA in China Accepted for Review Nicox announces acceptance of NCX 470 NDA in China by NMPA for review. Regulatory decision expected 12-18 months post-submission. Details on Ocumension and NCX 470 milestones China Nicox NCX 470 Regulatory Decision NMPA
BRIEF published on 09/02/2026 at 07:35, 1 month 29 days ago Nicox Extends Its Cash Flow Horizon Thanks to NCX 470 Ophthalmology NDA Nicox NCX 470 Cash Flow Horizon
BRIEF published on 09/02/2026 at 07:35, 1 month 29 days ago Nicox Announces Financial Stability Extension Financial Update Ophthalmology Nicox NCX 470 Cash Runway
PRESS RELEASE published on 09/02/2026 at 07:30, 1 month 29 days ago Nicox Announces Extension of Cash Runway Nicox extends cash runway with estimated €8.4 million as of 31 August 2026, supporting operations beyond Q1 2028. NCX 470 U.S. NDA approval milestone could fund operations into 2029 Financial Update Ophthalmology Nicox NCX 470 Cash Runway
BRIEF published on 08/27/2026 at 07:35, 2 months 4 days ago Nicox: PDUFA date set for the NCX 470 in April 2027 FDA Glaucoma Nicox NCX 470 PDUFA
PRESS RELEASE published on 08/27/2026 at 07:30, 2 months 4 days ago Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma Nicox announces April 2027 PDUFA date for NCX 470 in Glaucoma. Positive results from Phase 3 trials pave the way for potential FDA approval and commercial launch in H2 2027 FDA Approval Glaucoma Nicox NCX 470 PDUFA Date
Published on 10/30/2026 at 23:35, 22 hours 56 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 23 hours 1 minute ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 3 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 7 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 5 hours 55 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 23 hours 42 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 3 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 23 hours 31 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 10 hours ago Capital increase through exercise of subscription rights
